Plasma gelsolin explained

Symbol:Plasma Gelsolin
Plasma Gelsolin
Width:300
Pfam:PF00626
Pfam Clan:CL0092
Interpro:IPR007123
Scop:1vil
Pdb:,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Plasma gelsolin (pGSN) is an 83 kDa abundant protein constituent of normal plasma and an important component of the innate immune system. The identification of pGSN in Drosophila melanogaster[1] and C. elegans[2] points to an ancient origin early in evolution.[3] Its extraordinary structural conservation reflects its critical regulatory role in multiple essential functions. Its roles include the breakdown of filamentous actin released from dead cells, activation of macrophages, and localization of the inflammatory response. Substantial decreases in plasma levels are observed in acute and chronic infection and injury in both animal models and in humans. Supplementation therapies with recombinant human pGSN have been shown effective in more than 20 animal models.

pGSN has a cytoplasmic isoform (cGSN) known to be an actin-binding protein controlling cytoskeletal dynamics. cGSN is expressed from the same gene, and is identical to pGSN except for its lack of a 24 amino acid N-terminal extension.

History

The cellular isoform of Gelsolin was discovered in 1979 in the lab of Thomas P. Stossel. Its name comes from observed calcium-dependent reversible gel-sol transitions of macrophage cytoplasmic extract.[4] Around the same time a similarly sized plasma protein was discovered and shown to depolymerize actin; it was named Brevin, due to its ability to shorten actin filaments.[5] [6] [7] [8] [9] In 1986 it was demonstrated that Brevin was identical to cellular Gelsolin except for a 24 AA N-terminal extension, and was renamed Plasma Gelsolin.

Structure

Plasma Gelsolin is a 755 AA, 83 kDa plasma protein made up of six "gelsolin domains," each composed of a 5-6 strand β-sheet between one long and one short α-helix.[10] It exhibits a weak homology between domains S1 and S4, S2 and S5, and S3 and S6, and is identical to the cytoplasmic form of the protein except for the addition of a 24 AA N-terminal extension. Additionally a 27 AA N-terminal signal peptide is cleaved prior to pGSN's secretion from the cell. Both forms of the protein are encoded by highly conserved genes on chromosome 9 in humans, but are under the control of different promoters.[11] There is a single disulfide bond formed on the second domain of the plasma protein,[10] there are no documented natural post-translational modifications, and the pI ≈ 6.[12]

Isoforms and mutations

Aside from the cellular form, the only other known isoform is Gelsolin-3, an identical non-secreted protein containing an 11 AA, rather than 24 AA, N-terminal extension. It has been found in brain, testes, and lung oligodendrocytes, and is reportedly involved in myelin remodeling during spiralization around the axon.[13]

Plasma Gelsolin is highly conserved,[14] and its only known mutations are single point mutations.One of several such mutations leads to Finnish Familial Amyloidosis, a disorder in which pGSN becomes more conformationally flexible and susceptible to enzymatic cleavage resulting in accumulation of peptide fragments into amyloid fibrils.D187N/Y is the most common mutation with additional reports of G167R, N184K, P432R, A551P, and Ala7fs in the medical literature.[15] In addition to this several mutations as well as down-regulation of the protein are associated with breast cancer.[16]

Ca2+

At moderate pH in the absence of Ca2+ pGSN is compact and globular. Low pH or the presence of >nM Ca2+ is associated with an elongated structure with greater backbone flexibility.This flexibility exposes the actin binding sites.Since physiological levels of Ca2+ are ~2 mM, pGSN is natively elongated and able to bind to leaked actin from cellular damage.

Functions

Binding

Plasma Gelsolin is a sticky protein known to bind to a number of peptides and proteins:Actin (see: Relationships with actin),[17] [18] Apo-H,[19] Aβ,α-Synuclein,[20] Integrin,Tcp-1,[21] Fibronectin,[22] Syntaxin-4,[23] Tropomyosin,[24] fatty acids and phospholipids (see: Binding and inactivation of diverse inflammatory mediators): LPA,LPS (endotoxin),LTA,PAF,S1P, polyphosphoinositides including PIP2;[25] [26] [27] and nucleic acids: Ap3A,ATP,ADP.PIP2, a phospholipid component of cell membranes, competes with ATP and actin for pGSN binding,[28] and will dissociate F-Actin-capped pGSN.[29]

Relationships with actin

Actin toxicity and removal

Actin is the most abundant cellular protein, and its release into extracellular fluid and circulation following cellular injury from disease[30] or injury[31] leads to increased blood viscosity, hindered microcirculation,[32] and activation of platelets.[33] [34] Hemodialysis patients with low levels of pGSN and high levels of actin in blood had markedly higher mortality.[35] Actin is a major component of biofilms that accumulate at local sites of injury and infection, impeding access of host immune components and therapeutics such as antibiotics.Biofilms are particularly pathogenic in the setting of foreign bodies like indwelling catheters and tissue implants.

Actin exchanges between monomeric (G) and filamentous (F) forms according to the concentrations of it, ATP, and cations.[36] pGSN along with Vitamin D-binding protein (DBP) bind and clear monomeric actin. DBP binds with greater affinity to G-actin, leaving pGSN available to sever F-actin.[37] Furthermore, DBP is capable of removing one actin from a 2:1 actin-pGSN complex, restoring its ability to sever F-actin.[38] F-actin, severed and capped by pGSN, is removed by sinusoidal endothelial cells of the liver.[39] pGSN removes 60% of actin trapped in fibrin clots in vitro leading to an increased rate of clot lysis.

Severing, capping, nucleation, and polymerization

Although pGSN is capable of initiating the polymerization of actin through nucleation, its primary relationship with it in blood is depolymerization through filament severing. Actin severing occurs rapidly in the presence of pGSN and Ca2+.[40] pGSN wraps around filaments, non-enzymatically cleaving them.It remains attached, "capping" the barbed/plus end of the severed filament and inducing a torsional twist that is cooperative through its length.[41] [42] Capping has a reported binding affinity <250 pM in the presence of Ca2+ that is substantially weakened in its absence. Capping also blocks further polymerization at the fast growing, barbed end.[43]

While no evidence exists for nucleating/polymerizing of G-actin by pGSN in vivo, the ability of it to do so in vitro is well documented.[44] [45] Actin polymerization is initiated by the production of an actin trimer nucleus.[46] Formation of nuclei is energetically disfavored, but dimers and/or trimers can be catalyzed/stabilized by a number of cellular proteins.[47] In excess of a 2:1 actin:gelsolin stoichiometry and in the presence of Ca2+, gelsolin will bind three actin monomers.[48] A monomer adds to the trimer creating a tetramer that undergoes an internal conversion to an active tetramer witnessed by a concentration-independent lag phase. Subsequent fibrilization proceeds by monomer addition.[49] Gelsolin remains attached to the fast-growing (barbed/plus) end of actin, producing short, slow-growing fibrils.[50]

These actions are similar to those of cytoplasmic form of pGSN, cGSN, which contributes to structural changes of cells through both nucleating/polymerizing and severing/capping.[10]

Amyloid prevention and clearance

pGSN may play an important role in the prevention and management of amyloidosis in several diseases. It is found in complex with Aβ in plasma and reported to both inhibit amyloid formation and defibrillize preformed fibrils in vitro. Mice with an Alzheimer's disease model given pGSN showed a 5-fold decrease in progression of Cerebral Amyloid Angiopathy.[51] pGSN has also been found in Lewy Bodies, amyloid containing protein aggregates associated with Parkinson's disease and Dementia with Lewy bodies.[52] [53]

Role in inflammation

Macrophage stimulation

MARCO receptor

Macrophage receptor MARCO is responsible for pathogen recognition and phagocytosis. Macrophages incubated with actin at concentrations consistent with lung injury showed decreased uptake of bacteria. Uptake was restored when actin was administered in the presence of pGSN.[54]

NOS3

NOS3 is an enzyme that is protective against systemic inflammation and myocardial dysfunction.[55] [56] pGSN activates phosphorylation of Ser1177 in NOS3 and Ser473 in Akt.[57] NOS3 is known to be activated by phosphorylation of Akt.[58] Mouse macrophage uptake and killing of bacteria in vitro was enhanced by pGSN, and no significant enhancement was found for NOS3-/- macrophages.In vivo, mice showed 15-fold improvement in bacterial clearance when given pGSN, and no significant enhancement was found for NOS3-/- mice.[57]

Inflammatory mediators

pGSN has been shown to bind to the fatty acid inflammatory mediators LPA,[59] LPS (endotoxin),[59] [60] LTA,[60] PAF,S1P,and polyphosphoinositides including PIP2.[40] [26] [27] Mediators of inflammation, the body's innate healing mechanism, accumulate at the site of the injury to begin the processes of defense and repair, and the depletion of local pGSN allows them to do their work.

See Binding and inactivation of diverse inflammatory mediators

Therapeutic potential

The broad therapeutic potential of pGSN supplementation resides in the fact that the molecule embodies a multifunctional system contributing importantly to innate immunity rather than a pharmacologic intervention with selective and specific activities.

Plasma gelsolin's primary function is to keep inflammation local and enhance the function of the innate immune system. It functions through a pleiotropic mechanism of action; severing toxic filamentous actin (F-actin), binding inflammatory mediators, and enhancing pathogen clearance. These mechanisms are quite distinct from other anti-inflammatory agents that function as antagonists of individual mediators or inhibitors of specific enzymes, and work to ablate inflammation. Most systemic anti-inflammatory agents also suppress the immune system[61] [62] and often require caution in administration because they increase the risk of infection.[63] Plasma gelsolin is unique in that it has also been demonstrated to enhance the antimicrobial action of macrophages,[54] which engulf and digest cellular debris and pathogens, boosting immunity against both gram positive and gram negative bacterial infections.[57]

Mechanisms of action

Plasma gelsolin plays a central role in the body's innate immune system and is responsible for localizing inflammation—a mechanism so central to species survival that it has been highly conserved by evolution. Experimental and epidemiology data suggest that pGSN performs the role of a buffer or shield that modulates the inflammatory response to injury or infection. The system accomplishes this goal in three key ways described below:

Debridement

Plasma gelsolin binds and severs filamentous actin exposed from cells damaged by injury,[5] [6] [64] including both infectious and sterile injury. Actin has been reported to activate platelets,[34] interfere with fibrinolysis,[65] [66] damage endothelial cells,[67] and to function as a danger signal (DAMP).[68] Administration of large quantities of filamentous actin to rats resulted in lethal pulmonary hemorrhage and thrombosis.[32]

Another key “toxicity” of exposed actin is the fact that it is a major component of biofilms that accumulate at local sites of injury and infection, and that it impedes the access of host immune components and therapeutics such as antibiotics.[69] Biofilms are particularly pathogenic in the setting of foreign bodies like indwelling catheters and tissue implants.[70] As a result of actin exposure at the local site of injury, the local level of plasma gelsolin around the site of the injury initially becomes depleted as it “debrides” the local involved site. Mediators of inflammation, the body's innate healing mechanism, accumulate at the site of the injury to begin the processes of defense and repair, and the depletion of local plasma gelsolin allows them to do their work. While local pGSN levels are depressed, the presence of this abundant protein in the circulation ensures that the inflammatory process stays local, and that stores of plasma gelsolin are available to address further injury so that the overall immune response remains intact.

Augmentation of macrophage antimicrobial activity

pGSN has antimicrobial activity in vitro and in vivo. Administration of pGSN subcutaneously or by inhalation to mice challenged with lethal inocula of S. pneumoniae or even more lethal combinations of influenza virus and bacteria markedly diminished the number of viable bacteria in the animals’ airways and significantly reduced mortality. The number of inflammation-inducing neutrophils was also considerably reduced, presumably as a result of enhanced bacterial clearance. This is true for contemporaneous or delayed administration of recombinant pGSN.[57] [71]

A basis of pGSN's antimicrobial action is that it enhances the ability of cultivated lung macrophages to ingest gram positive and gram negative bacteria. This has been demonstrated in vitro.[57] Improved phagocytosis is the product of pGSN debriding actin bound to macrophage scavenger receptors preventing their function.[54] pGSN also increases the ability of macrophages to kill ingested microorganisms by inducing macrophage nitric oxide synthase activity.[57]

Binding and inactivation of diverse inflammatory mediators

pGSN binds to a number of inflammatory mediators and signaling agents.Binding to LPA occurs at the same site on the molecule that ligates actin and interacts with polyphosphoinositides. Subsequent studies showed that gelsolin alters the effector function of LPA's receptor binding. Binding to inflammatory mediators, and in some cases inhibition of their effector function, has been shown for platelet-activating factor, lipopolysaccharide endotoxin, sphingosine-1-phosphate,[60] and lipoteichoic acid and small molecule purinergic agonists including ATP and ADP.[72] [73] [74] [75] The binding of pGSN to Aβ Alzheimer peptide has also been well documented.[76]

Role of mediators which bind to plasma gelsolin
Mediator Role
LPA[77] [78] A phospholipid derivative that can act as a signaling molecule and activates G protein coupled receptors. It has been associated with cell proliferation.
LPS/endotoxin[79] Found in the outer membrane of Gram-negative bacteria, it elicits a strong immune response in animals.
PAF[80] A potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells.
Aβ[81] [82] A peptide of 36–43 amino acids that is the main constituent of amyloid plaques in the brains of Alzheimer's disease patients.
A major constituent of the cell wall of Gram-positive bacteria able to stimulate a specific immune response in animals.
S1P[83] A blood borne lipid mediator and major regulator of vascular and immune systems. In the vascular system, S1P regulates angiogenesis, vascular stability, and permeability. In the immune system it is recognized as a major regulator of trafficking of T-cells and B-cells. Inhibition of S1P receptors has been shown to be critical for immunomodulation.

Anti-microbial resistance

Antimicrobial resistance is a global threat that leads to an estimated 700,000 deaths annually with projections of 10M deaths per year and lost economic potential of $100T by 2050.[84] [85] The United States has released a national action plan to combat antibiotic resistant bacteria.[86]

Recombinant pGSN (rhu-pGSN) supplementation alone shows improved survival and decreased bacteria counts in several mouse models.[71] [87] The bactericidal activity of the antimicrobial peptide LL-37 was shown to be inhibited by F-actin. It formed bundles with F-actin in vitro that were dissolved by pGSN, restoring bactericidal activity. Bacteria growth was reduced when pGSN was added cystic fibrosis sputum, which is known to contain F-actin.[88]

When mice were given a penicillin-resistant strain of pneumococcal pneumonia, penicillin had no effect on mortality or morbidity. rhu-pGSN improved both mortality and morbidity on its own, and the combination of rhu-pGSN and penicillin gave further improvement of both suggesting possible synergism.[87]

Levels of the Protein

Plasma gelsolin is produced and secreted by virtually every cell type with muscle contributing the largest amount.[89] At normal levels of >200 mg/L, it is a highly abundant protein in the circulation.

Decreased levels are often associated with ill health and disease.[90] [91] A growing list of insults showing loss of pGSN includes pneumonia,[92] sepsis,[93] SIRS,[94] traumatic brain injury,[95] autoimmune diseases,[96] chronic kidney disease,HIV-1 disease,[97] tick-borne encephalitis and Lyme,[98] malaria,[99] [100] hepatitis,[101] burns,[102] [103] multiple organ dysfunction syndrome,[102] trauma associated with injury[104] or surgery,[105] bone marrow transplantation,[106] and multiple sclerosis.[107] Severely depleted levels (<150 mg/L) strongly correlate with the onset of systemic inflammatory dysregulation and predict increased morbidity and mortality across a broad spectrum of clinical presentations in the critical care setting. The magnitude of decline in pGSN correlates with the likelihood of mortality in seriously ill patients.[108]

Mediators of inflammation, the body's innate healing mechanism, accumulate at the site of the injury to begin the processes of defense and repair,[109] [110] [111] and the depletion of local plasma gelsolin allows them to do their work.[112] As a result of actin exposure at the local site of injury, the local level of plasma gelsolin around the site of the injury initially becomes depleted as it “debrides” the local involved site (see: Debridement).While local pGSN levels are depressed, the presence of this abundant protein in the circulation ensures that the inflammatory process stays local,[91] and that stores of plasma gelsolin are available to address further injury so that the overall immune response remains intact (see: Binding and inactivation of diverse inflammatory mediators).

Measured levels are higher in serum than plasma due to pGSN's affinity for fibrin.[113]

Animal studies

Human plasma gelsolin has been produced in recombinant form in E. coli (rhu-pGSN), and its efficacy as a therapeutic has been studied in vivo in a number of animal models of inflammatory disease. In models of injury that cause actin release and inflammatory organ damage, pGSN levels consistently drop. In models where gelsolin levels are replenished, adverse outcomes can be prevented. To date, rhu-pGSN has been studied in many independent laboratories providing evidence of efficacy in >20 animal models. Following are descriptions of selected animal studies. All stated results are relative to those of placebo treatments.

Summary of clinical results from selected animal studies
Disease Model Results
mouse Mice given a highly lethal form of influenza show increased survival at 12 day end of study point as well as decreased morbidity and decreased expression of pro-inflammatory genes when rhu-pGSN is administered 3 to 6 days after infection.[114]
mouse Mice were given pneumococcal challenge 7 days after being given influenza. Supplementation of endogenous pGSN with rhu-pGSN improved bacterial clearance 15-fold, reduced neutrophilic inflammation, improved recovery of initial weight loss, and showed a dose-dependent improvement on survival. No antibiotics were given, demonstrating pGSN's ability to stimulate the innate immune response.
rat Rats receiving 40% body surface area burn showed 90% loss of endogenous pGSN within 12 hours and slowly recovered to almost 50% after 6 days. Intravenous administration of rhu-pGSN partially or totally prevented the burn-associated increase in pulmonary microvascular permeability in a dose-dependent manner.[115] See also[116]
mouse Mice were intraperitoneally injected with endotoxin (LPS) or subjected to cecal ligation and puncture (CLP) (a small amount of intestinal contents were extracted into the cavity and the wound was sutured). Endogenous pGSN levels dropped to 50% post-challenge. Survival substantially improved with rhu-pGSN treatment in both groups: LPS study, 90% vs 0%; CLP study: 30% vs 0%.[117]
sepsis rat Relative to a previous mouse study a smaller dosage of rhu-pGSN decreased morbidity in a double CLP sepsis model relative to sham treatments. The dosage was effective in intraveneous and subcutaneous injections, but less so with intraperitoneal injection (qualitative but not statistically significant) despite the latter being the site of injury. This evidenced the need for systemic availability of pGSN for recovery.[118]
mouse Mice were subjected to 95% O2 for 72 hr and treated with rhu-pGSN after 24 and 48 hr. Hyperoxia produced severe diffuse congestion and edema with hemorrhage visible in lung histopathology, 70% reduction in endogenous pGSN, and an influx of neutrophils. Treatment with rhu-pGSN led to a 23% decrease in the authors' histpathological score, 65% decrease in BAL fluid neutrophil count, and a 29% reduction in an overall acute lung injury score.[119]
rat Researchers induced middle cerebral artery occlusion with a direct injection of Endothelin 1, a vasoconstrictor. Animals treated with pGSN at the site of injury exhibited 50% infarction area, >2x use of both forepaws during exploration, and a decrease in whisker-stimulated reaction time (9 s, pGSN treated; 19 s untreated; 1 s healthy rat).[120]
mouse Mice with experimental autoimmune encephalomyelitis show decreased levels of pGSN in blood and increased levels in the brain. All rhu-pGSN-treated mice survived whereas 60% of control died within 30 days. Rhu-pGSN mice scored significantly better on clinical scores, smaller brain lesions imaged by MRI, less extra-cellular actin, and decreased myeloperoxidase activity.[121]
mouse Two models of Alzheimer's were tested. Treatment mice that were tail-injected with a plasmid encoding human pGSN showed reduction in Aβ42 in brain tissue, decreased amyloid, and increased concentration of microglia.[122] See also[123]
mouse Mice irradiated with 137Cs γ-rays show a 50-75% decrease in endogenous levels of pGSN. Bleeding is a common consequence of heavy radiation exposure. Administration of rhu-pGSN improved clotting indices in later, but not middle, phases of recovery. Rhu-pGSN improved GSH and MDA oxidative stress indices.[124]
mouse Intraperitoneal injection of acetic acid causes a pain response quantified by writhing.[125] Both rhu-pGSN and diclofenac sodium (DS), a standard analgesic drug, caused ~55% reduction in writhing. Similarly, tails placed in hot water caused mice to retract them in an average time of 2.3 s. DS increased time to withdrawal from 5.1 to 7.6 s depending on time of drug administration; rhu-pGSN increased time from 2.9 to 5.5 s. Both DS and rhu-pGSN showed significant reductions in swelling associated with paw injection of an inflammatory agent, γ-carrageenan, as well as decreases in measured cytokines TNF-α and IL-6.[126]
mouse Endogenous levels of pGSN decrease by ~50% with type 2 diabetes(T2D) in both humans and mice. In an oral glucose tolerance test, rhu-pGSN brought blood sugar levels down to levels comparable to sitagliptin, a T2D drug. Daily dose of rhu-pGSN kept blood sugar levels close to normal for the 7 days of treatment. Daily dose of sitagliptin increased levels of endogenous pGSN.[127]

Human Studies

In 2019 BioAegis Therapeutics conducted a Phase Ib/IIa safety study administering recombinant human pGSN to sick patients with community acquired pneumonia; no safety issues were found.[128] A 2020 Phase IIb placebo-controlled efficacy study has been approved for acute severe pneumonia due to COVID-19. The primary outcome was the proportion of patients surviving on Day 14 without mechanical ventilation, vasopressors, or dialysis. Evaluation of efficacy of rhu-pGSN was confounded by high survival rates of both treatment and placebo cohorts resulting from improvements made to the standard of care for COVID pneumonia.[129]

See also

Cytoplasmic gelsolin

Actin

Vitamin D-binding protein

Notes and References

  1. Shi. Yigong. 2004-08-01. Caspase activation, inhibition, and reactivation: A mechanistic view. Protein Science. 13. 8. 1979–1987. 10.1110/ps.04789804. 15273300. 2279816. 0961-8368.
  2. Klaavuniemi. Tuula. Yamashiro. Sawako. Ono. Shoichiro. 2008-09-19. Caenorhabditis elegans Gelsolin-like Protein 1 Is a Novel Actin Filament-severing Protein with Four Gelsolin-like Repeats. Journal of Biological Chemistry. 283. 38. 26071–26080. 10.1074/jbc.M803618200. 18640981. 2533794. 0021-9258. free.
  3. 10.1002/bies.20200. 1521-1878. 27. 4. 388–396. Archer. Stuart K.. Claudianos. Charles. Campbell. Hugh D.. Evolution of the gelsolin family of actin-binding proteins as novel transcriptional coactivators. BioEssays. 2005. 15770676. 40585071.
  4. Yin . Helen L. . Stossel . Thomas P. . Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein . Nature . 18 October 1979 . 281 . 5732 . 583–586 . 10.1038/281583a0 . 492320 . 1979Natur.281..583Y . 4250013 . 13 February 2020.
  5. 10.1007/bf01949928. 0014-4754. 35. 8. 1039–1041. Chaponnier. C.. Borgia. R.. Rungger-Brändle. E.. Weil. R.. Gabbiani. G.. An actin-destabilizing factor is present in human plasma. Experientia. 1979-08-15. 477868. 21319139.
  6. 10.1111/j.1432-1033.1979.tb04204.x. 0014-2956. 100. 2. 575–583. Norberg. Renee. Thorstensson. Rigmor. Utter. Goran. Fagraeus. Astrid. F-Actin-Depolymerizing Activity of Human Serum. European Journal of Biochemistry. 1979-10-15. 389627.
  7. 10.1016/0014-5793(80)81291-9. 0014-5793. 121. 1. 175–177. Harris. H.E.. Bamburg. J.R.. Weeds. A.G.. Actin filament disassembly in blood plasma. FEBS Letters. 1980-11-17. 6893965. 30794630. free.
  8. 10.1016/0014-5793(81)80017-8. 0014-5793. 123. 1. 49–53. Harris. H.E.. Gooch. J.. An actin depolymerizing protein from pig plasma. FEBS Letters. 1981-01-12. 6894126. 27405593. free.
  9. 10.1073/pnas.78.11.6798. 0027-8424. 78. 11. 6798–6802. Harris. D. A.. Schwartz. J. H.. Characterization of brevin, a serum protein that shortens actin filaments. Proceedings of the National Academy of Sciences. 1981-11-01. 6947253. 349138. 1981PNAS...78.6798H. free.
  10. 10.1002/cm.21117. 1949-3584. 70. 7. 360–384. Nag. Shalini. Larsson. Mårten. Robinson. Robert C.. Burtnick. Leslie D.. Gelsolin: The tail of a molecular gymnast: Gelsolin Superfamily Proteins. Cytoskeleton. 2013-06-10. 23749648. free.
  11. 10.1038/323455a0. 0028-0836. 323. 6087. 455–458. Kwiatkowski. D. J.. Stossel. T. P.. Orkin. S. H.. Mole. J. E.. Colten. H. R.. Yin. H. L.. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature. 1986-10-02. 3020431. 1986Natur.323..455K. 4356162.
  12. 0021-9258. 259. 8. 5271–5276. Yin. H. L.. Kwiatkowski. D. J.. Mole. J. E.. Cole. F. S.. Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin.. Journal of Biological Chemistry. 2020-03-02. 1984-04-25. 10.1016/S0021-9258(17)42985-1. 6325429. free.
  13. 10.1046/j.1471-4159.1997.69030995.x. 0022-3042. 69. 3. 995–1005. Vouyiouklis. Demetrius A.. Brophy. Peter J.. A Novel Gelsolin Isoform Expressed by Oligodendrocytes in the Central Nervous System. Journal of Neurochemistry. 2002-11-18. 9282921. 44552710.
  14. Lee. William M.. Galbraith. Robert M.. 1992-05-14. The Extracellular Actin-Scavenger System and Actin Toxicity. New England Journal of Medicine. 326. 20. 1335–1341. 10.1056/NEJM199205143262006. 0028-4793. 1314333.
  15. 10.1073/pnas.1902189116. 0027-8424. 116. 28. 13958–13963. Zorgati. Habiba. Larsson. Mårten. Ren. Weitong. Sim. Adelene Y. L.. Gettemans. Jan. Grimes. Jonathan M.. Li. Wenfei. Robinson. Robert C.. The role of gelsolin domain 3 in familial amyloidosis (Finnish type). Proceedings of the National Academy of Sciences. 2019-07-09. 31243148. 6628662. 2019PNAS..11613958Z. free.
  16. 10.1155/2013/795410. 0278-0240. 34. 2. 71–80. Baig. Ruqia Mehmood. Mahjabeen. Ishrat. Sabir. Maimoona. Masood. Nosheen. Ali. Kashif. Malik. Faraz Arshad. Kayani. Mahmood Akhtar. Mutational Spectrum of Gelsolin and Its Down Regulation Is Associated with Breast Cancer. Disease Markers. 2013. 23324580. 3809971. free.
  17. 10.1007/BF01766670. 0142-4319. 11. 4. 323–330. Edgar. Alasdair John. Gel electrophoresis of native gelsolin and gelsolin-actin complexes. Journal of Muscle Research and Cell Motility. 1990-08-01. 2174905. 11355042.
  18. 10.1038/sj.emboj.7600280. 0261-4189. 23. 14. 2713–2722. Burtnick. Leslie D. Urosev. Dunja. Irobi. Edward. Narayan. Kartik. Robinson. Robert C. Structure of the N-terminal half of gelsolin bound to actin: roles in severing, apoptosis and FAF. The EMBO Journal. 2004-07-21. 15215896. 514944.
  19. 10.1111/j.1582-4934.2009.00940.x. 1582-1838. 15. 1. 141–151. Bohgaki. Miyuki. Matsumoto. Masaki. Atsumi. Tatsuya. Kondo. Takeshi. Yasuda. Shinsuke. Horita. Tetsuya. Nakayama. Keiichi I.. Okumura. Fumihiko. Hatakeyama. Shigetsugu. Koike. Takao. Plasma gelsolin facilitates interaction between β2 glycoprotein I and α5β1 integrin. Journal of Cellular and Molecular Medicine. 2011-01-24. 19840195. 3822501.
  20. 10.1016/j.bbrc.2011.07.027. 0006-291X. 412. 1. 32–38. Welander. Hedvig. Bontha. Sai Vineela. Näsström. Thomas. Karlsson. Mikael. Nikolajeff. Fredrik. Danzer. Karin. Kostka. Marcus. Kalimo. Hannu. Lannfelt. Lars. Ingelsson. Martin. Bergström. Joakim. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro. Biochemical and Biophysical Research Communications. 2011-08-19. 21798243.
  21. 10.1007/s12192-015-0637-5. 1355-8145. 21. 1. 55–62. Svanström. Andreas. Grantham. Julie. The molecular chaperone CCT modulates the activity of the actin filament severing and capping protein gelsolin in vitro. Cell Stress and Chaperones. 2015-09-12. 26364302. 4679748.
  22. 0021-9258. 259. 21. 13262–13266. Lind. S. E.. Janmey. P. A.. Human plasma gelsolin binds to fibronectin. The Journal of Biological Chemistry. 1984-11-10. 10.1016/S0021-9258(18)90687-3. 6092370. free.
  23. 10.1210/me.2011-1112. 0888-8809. 26. 1. 128–141. Kalwat. Michael A.. Wiseman. Dean A.. Luo. Wei. Wang. Zhanxiang. Thurmond. Debbie C.. Gelsolin Associates with the N Terminus of Syntaxin 4 to Regulate Insulin Granule Exocytosis. Molecular Endocrinology. 2012-01-01. 22108804. 3248323.
  24. 10.1111/febs.12431. 1742-4658. 280. 18. 4600–4611. Khaitlina. Sofia. Fitz. Helene. Hinssen. Horst. The interaction of gelsolin with tropomyosin modulates actin dynamics. The FEBS Journal. 2013-07-11. 23844991. free.
  25. 10.1038/325362a0. 0028-0836. 325. 6102. 362–364. Janmey. P. A.. Stossel. T. P.. Modulation of gelsolin function by phosphatidylinositol 4,5-bisphosphate. Nature. 1987-01-22. 3027569. 1987Natur.325..362J. 4324043.
  26. 10.1074/jbc.272.33.20443. 0021-9258. 272. 33. 20443–20450. Lin. Keng-Mean. Wenegieme. Elizabeth. Lu. Pei-Jung. Chen. Ching-Shih. Yin. Helen L.. Gelsolin Binding to Phosphatidylinositol 4,5-Bisphosphate Is Modulated by Calcium and pH. Journal of Biological Chemistry. 1997-08-15. 9252353. free.
  27. 10.1083/jcb.138.4.811. 0021-9525. 138. 4. 811–820. Sun. Hui-qiao. Lin. Keng-mean. Yin. Helen L.. Gelsolin Modulates Phospholipase C Activity In Vivo through Phospholipid Binding. The Journal of Cell Biology. 1997-08-25. 9265648. 2138049.
  28. 10.1371/journal.pone.0201826. 1932-6203. 13. 8. –0201826. Szatmári. Dávid. Xue. Bo. Kannan. Balakrishnan. Burtnick. Leslie D.. Bugyi. Beáta. Nyitrai. Miklós. Robinson. Robert C.. Eugene A. Permyakov (ed.). ATP competes with PIP2 for binding to gelsolin. PLOS ONE. 2018-08-07. 30086165. 6080781. 2018PLoSO..1301826S. free.
  29. 0021-9258. 262. 25. 12228–12236. Janmey. P. A.. Iida. K.. Yin. H. L.. Stossel. T. P.. Polyphosphoinositide micelles and polyphosphoinositide-containing vesicles dissociate endogenous gelsolin-actin complexes and promote actin assembly from the fast-growing end of actin filaments blocked by gelsolin. The Journal of Biological Chemistry. 1987-09-05. 10.1016/S0021-9258(18)45341-0. 3040735. free.
  30. 10.1164/ajrccm.162.1.9806088. 1073-449X. 162. 1. 288–294. Erukhimov. Jeffrey A.. Tang. Zi-Lue. Johnson. Bruce A.. Donahoe. Michael P.. Razzack. Jamal A.. Gibson. Kevin F.. Lee. William M.. Wasserloos. Karla J.. Watkins. Simon A.. Pitt. Bruce R.. Actin-Containing Sera From Patients With Adult Respiratory Distress Syndrome Are Toxic to Sheep Pulmonary Endothelial Cells. American Journal of Respiratory and Critical Care Medicine. July 2000. 10903256. 23974368.
  31. 10.1136/bjsm.2004.017566. 0306-3674. 39. 11. 830–834. Martinez-Amat. A. Release of α-actin into serum after skeletal muscle damage. British Journal of Sports Medicine. 2005-11-01. 16244192. 1725075.
  32. Haddad. J G. Harper. K D. Guoth. M. Pietra. G G. Sanger. J W. February 1990. Angiopathic consequences of saturating the plasma scavenger system for actin.. Proceedings of the National Academy of Sciences of the United States of America. 87. 4. 1381–1385. 10.1073/pnas.87.4.1381. 0027-8424. 53479. 2154744. 1990PNAS...87.1381H. free.
  33. 10.1016/0006-291X(81)91967-7. 0006-291X. 100. 3. 1314–1319. Scarborough. Victoria D.. Bradford. Harvey R.. Ganguly. Pankaj. Aggregation of platelets by muscle actin. A multivalent interaction model of platelet aggregation by ADP. Biochemical and Biophysical Research Communications. 1981-06-16. 6895029.
  34. 10.1182/blood.V82.12.3648.bloodjournal82123648. 0006-4971. 82. 12. 3648–3657. Vasconcellos. Ca. Lind. Se. Coordinated inhibition of actin-induced platelet aggregation by plasma gelsolin and vitamin D-binding protein. Blood. 2020-02-13. 1993-12-15. 2024-04-27. 8260702. free.
  35. Lee. Po-Shun. Sampath. Kartik. Karumanchi. S. Ananth. Tamez. Hector. Bhan. Ishir. Isakova. Tamara. Gutierrez. Orlando M.. Wolf. Myles. Chang. Yuchiao. Stossel. Thomas P.. Thadhani. Ravi. 2009-04-23. Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality. Journal of the American Society of Nephrology. 20. 5. 1140–1148. 10.1681/ASN.2008091008. 19389844. 2678046. 1046-6673.
  36. 10.1002/bip.22155. 0006-3525. 99. 4. 245–256. Kudryashov. Dmitri S.. Reisler. Emil. ATP and ADP Actin States. Biopolymers. April 2013. 23348672. 3670783.
  37. 10.1172/JCI112634. 0021-9738. 78. 3. 736–742. Lind. S E. Smith. D B. Janmey. P A. Stossel. T P. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation.. Journal of Clinical Investigation. 1986-09-01. 3018044. 423663.
  38. 10.1016/0006-291X(86)90878-8. 0006-291X. 136. 1. 72–79. Janmey. Paul A.. Stossel. Thomas P.. Lind. Stuart E.. Sequential binding of actin monomers to plasma gelsolin and its inhibition by vitamin D-binding protein. Biochemical and Biophysical Research Communications. 1986-04-14. 3010978.
  39. Herrmannsdoerfer. A. J.. Heeb. G. T.. Feustel. P. J.. Estes. J. E.. Keenan. C. J.. Minnear. F. L.. Selden. L.. Giunta. C.. Flor. J. R.. Blumenstock. F. A.. December 1993. Vascular clearance and organ uptake of G- and F-actin in the rat. The American Journal of Physiology. 265. 6 Pt 1. –1071–1081. 10.1152/ajpgi.1993.265.6.G1071. 0002-9513. 8279558.
  40. 0006-4971. 70. 2. 524–530. Janmey. P. A.. Lind. S. E.. Capacity of human serum to depolymerize actin filaments. Blood. August 1987. 10.1182/blood.V70.2.524.524. 3038216. free.
  41. 10.1006/jmbi.1994.0049. 0022-2836. 245. 5. 598–607. Orlova. A.. Prochniewicz. E.. Egelman. E. H.. Structural dynamics of F-actin: II. Cooperativity in structural transitions. Journal of Molecular Biology. 1995-02-03. 7844829.
  42. 10.1006/jmbi.1996.0435. 0022-2836. 260. 5. 756–766. Prochniewicz. Ewa. Zhang. Qingnan. Janmey. Paul A.. Thomas. David D.. Cooperativity in F-Actin: Binding of Gelsolin at the Barbed End Affects Structure and Dynamics of the Whole Filament. Journal of Molecular Biology. August 1996. 8709153.
  43. 10.1021/bi00335a046. 0006-2960. 24. 14. 3714–3723. Janmey. Paul A.. Chaponnier. Christine. Lind. Stuart E.. Zaner. Ken S.. Stossel. Thomas P.. Yin. Helen L.. Interactions of gelsolin and gelsolin-actin complexes with actin. Effects of calcium on actin nucleation, filament severing, and end blocking. Biochemistry. July 1985. 2994715.
  44. 0021-9258. 259. 19. 11868–11875. Doi. Y.. Frieden. C.. Actin polymerization. The effect of brevin on filament size and rate of polymerization.. Journal of Biological Chemistry. 2020-02-19. 1984-10-10. 10.1016/S0021-9258(20)71292-5. 6480587. free.
  45. 10.1529/biophysj.107.123125. 0006-3495. 95. 3. 1050–1062. Brooks. F.J.. Carlsson. A.E.. Actin Polymerization Overshoots and ATP Hydrolysis as Assayed by Pyrene Fluorescence. Biophysical Journal. August 2008. 18390612. 2479571. 2008BpJ....95.1050B.
  46. 10.1016/S0006-3495(01)75731-1. 0006-3495. 81. 2. 667–674. Sept. David. McCammon. J. Andrew. Thermodynamics and Kinetics of Actin Filament Nucleation. Biophysical Journal. 2001-08-01. 11463615. 1301543. 2001BpJ....81..667S.
  47. 10.1111/febs.13381. 1742-464X. 282. 19. 3824–3840. Qu. Zheng. Silvan. Unai. Jockusch. Brigitte M.. Aebi. Ueli. Schoenenberger. Cora-Ann. Mannherz. Hans Georg. Distinct actin oligomers modulate differently the activity of actin nucleators. FEBS Journal. October 2015. 26194975. free.
  48. 10.1007/BF01766670. 0142-4319. 11. 4. 323–330. Edgar. Alasdair John. Gel electrophoresis of native gelsolin and gelsolin-actin complexes. Journal of Muscle Research and Cell Motility. August 1990. 2174905. 11355042.
  49. 0021-9258. 259. 14. 8794–8800. Lal. A. A.. Korn. E. D.. Brenner. S. L.. Rate constants for actin polymerization in ATP determined using cross-linked actin trimers as nuclei. The Journal of Biological Chemistry. 1984-07-25. 10.1016/S0021-9258(17)47223-1. 6746624. free.
  50. 10.1007/BF01753587. 1573-2657. 7. 5. 446–454. Janmey. Paul A.. Stossel. Thomas P.. Kinetics of actin monomer exchange at the slow growing ends of actin filaments and their relation to the elongation of filaments shortened by gelsolin. Journal of Muscle Research & Cell Motility. 1986-10-01. 3025252. 2644111.
  51. 71. 11. 1009–17. Gregory. Julia L. Prada. Claudia M. Fine. Sara J. Garcia-Alloza. Monica. Betensky. Rebecca A. Arbel-Ornath. Michal. Greenberg. Steven M. Bacskai. Brian J. Frosch. Matthew P. Reducing Available Soluble A-Amyloid Prevents Progression of Cerebral Amyloid Angiopathy in Transgenic Mice. J Neuropathol Exp Neurol. 2012. 10.1097/NEN.0b013e3182729845. 23095848. 3491571.
  52. 10.1111/j.1750-3639.2007.00048.x. 1015-6305. 17. 2. 139–145. Leverenz. James B.. Umar. Imran. Wang. Qing. Montine. Thomas J.. McMillan. Pamela J.. Tsuang. Debby W.. Jin. Jinghua. Pan. Catherine. Shin. Jenny. Zhu. David. Zhang. Jing. Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathology (Zurich, Switzerland). 2007-04-01. 17388944. 24457175. 8095629.
  53. 10.1016/j.bbrc.2011.07.027. 0006-291X. 412. 1. 32–38. Welander. Hedvig. Bontha. Sai Vineela. Näsström. Thomas. Karlsson. Mikael. Nikolajeff. Fredrik. Danzer. Karin. Kostka. Marcus. Kalimo. Hannu. Lannfelt. Lars. Ingelsson. Martin. Bergström. Joakim. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro. Biochemical and Biophysical Research Communications. 2011-07-21. 21798243.
  54. 10.1152/ajplung.00067.2017. 1040-0605. 312. 6. –1018–L1028. Ordija. Christine M.. Chiou. Terry Ting-Yu. Yang. Zhiping. Deloid. Glen M.. de Oliveira Valdo. Melina. Wang. Zhi. Bedugnis. Alice. Noah. Terry L.. Jones. Samuel. Koziel. Henry. Kobzik. Lester. Free actin impairs macrophage bacterial defenses via scavenger receptor MARCO interaction with reversal by plasma gelsolin. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2017-06-01. 28385809. 5495953.
  55. 10.1097/SHK.0b013e3181cdc327. 1073-2322. 34. 3. 281–290. Bougaki. Masahiko. Searles. Robert J.. Kida. Kotaro. De Yu. Jia. Buys. Emmanuel S.. Ichinose. Fumito. NOS3 protects against systemic inflammation and myocardial dysfunction in murine polymicrobial sepsis. Shock (Augusta, Ga.). 2010-09-01. 19997049. 3774000.
  56. 10.1186/1471-2350-13-58. 1471-2350. 13. 1. 58. Jimenez-Sousa. Ma Angeles. López. Elisabeth. Fernandez-Rodríguez. Amanda. Tamayo. Eduardo. Fernández-Navarro. Pablo. Segura-Roda. Laura. Heredia. María. Gómez-Herreras. José I.. Bustamante. Jesús. García-Gómez. Juan Miguel. Bermejo-Martin. Jesús F.. Resino. Salvador. Genetic polymorphisms located in genes related to immune and inflammatory processes are associated with end-stage renal disease: a preliminary study. BMC Medical Genetics. 2012-07-20. 22817530. 3412707. free.
  57. 10.1152/ajplung.00094.2015. 1040-0605. 309. 1. –11–L16. Yang. Zhiping. Chiou. Terry Ting-Yu. Stossel. Thomas P.. Kobzik. Lester. Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2015-07-01. 25957291. 4491512.
  58. 10.1210/er.2001-0045. 0163-769X. 23. 5. 665–686. Chambliss. Ken L.. Shaul. Philip W.. Estrogen Modulation of Endothelial Nitric Oxide Synthase. Endocrine Reviews. October 2002. 12372846. free.
  59. 10.1016/j.bbamem.2005.12.009. 0005-2736. 1758. 1. 85–89. Mintzer. Evan. Sargsyan. Hasmik. Bittman. Robert. Lysophosphatidic acid and lipopolysaccharide bind to the PIP2-binding domain of gelsolin. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2006-01-18. 16460666. free.
  60. 10.4049/jimmunol.181.7.4936. 0022-1767. 181. 7. 4936–4944. Bucki. Robert. Byfield. Fitzroy J.. Kulakowska. Alina. McCormick. Margaret E.. Drozdowski. Wieslaw. Namiot. Zbigniew. Hartung. Thomas. Janmey. Paul A.. Extracellular Gelsolin Binds Lipoteichoic Acid and Modulates Cellular Response to Proinflammatory Bacterial Wall Components. The Journal of Immunology. 2008-10-01. 18802097. free.
  61. 10.1016/j.cellimm.2009.03.007. 0008-8749. 258. 1. 18–28. Bancos. Simona. Bernard. Matthew P.. Topham. David J.. Phipps. Richard P.. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cellular Immunology. 2009. 19345936. 2693360.
  62. 10.1016/j.mce.2010.04.005. 0303-7207. 335. 1. 2–13. Coutinho. Agnes E.. Chapman. Karen E.. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Molecular and Cellular Endocrinology. 2011-03-15. 20398732. 3047790.
  63. 1076-2191. 11. 6. 277–285. Gm. Anstead. Steroids, retinoids, and wound healing.. Advances in Wound Care: The Journal for Prevention and Healing. 1998-10-01. 10326344.
  64. 0006-4971. 70. 2. 524–530. Janmey. P. A.. Lind. S. E.. Capacity of human serum to depolymerize actin filaments. Blood. 1987-08-01. 10.1182/blood.V70.2.524.524. 3038216. free.
  65. 0006-4971. 80. 4. 928–936. Janmey. P. A.. Lamb. J. A.. Ezzell. R. M.. Hvidt. S.. Lind. S. E.. Effects of actin filaments on fibrin clot structure and lysis. Blood. 1992-08-15. 10.1182/blood.V80.4.928.928. 1323346. free.
  66. 266. 8. 5273–5278. Stuart E LindS. Smith. Carolyn J. Actin Is a Noncompetitive Plasmin Inhibitor. Journal of Biological Chemistry. 1991-03-15. 10.1016/S0021-9258(19)67783-5. 1848244. free.
  67. 10.1164/ajrccm.162.1.9806088. 1073-449X. 162. 1. 288–294. Erukhimov. Jeffrey A.. Tang. Zi-Lue. Johnson. Bruce A.. Donahoe. Michael P.. Razzack. Jamal A.. Gibson. Kevin F.. Lee. William M.. Wasserloos. Karla J.. Watkins. Simon A.. Pitt. Bruce R.. Actin-Containing Sera From Patients With Adult Respiratory Distress Syndrome Are Toxic to Sheep Pulmonary Endothelial Cells. American Journal of Respiratory and Critical Care Medicine. 2000-07-01. 10903256. 23974368.
  68. 10.15252/emmm.201607227. 1757-4684. 9. 3. 285–288. Sousa. Caetano Reis e. Sensing infection and tissue damage. EMBO Molecular Medicine. 2017-03-01. 28119319. 5331196.
  69. 10.1099/jmm.0.005728-0. 0022-2615. 58. Pt 4. 492–502. Parks. Quinn M.. Young. Robert L.. Poch. Katie R.. Malcolm. Kenneth C.. Vasil. Michael L.. Nick. Jerry A.. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. Journal of Medical Microbiology. 2009-04-01. 19273646. 2677169.
  70. 10.1128/IAI.73.6.3693-3701.2005. 0019-9567. 73. 6. 3693–3701. Walker. T. S.. Tomlin. K. L.. Worthen. G. S.. Poch. K. R.. Lieber. J. G.. Saavedra. M. T.. Fessler. M. B.. Malcolm. K. C.. Vasil. M. L.. Nick. J. A.. Enhanced Pseudomonas aeruginosa Biofilm Development Mediated by Human Neutrophils. Infection and Immunity. 2005-06-01. 15908399. 1111839.
  71. 10.1093/ofid/ofx163.1215. 2328-8957. 4. Suppl 1. –474–S475. Yang. Zhiping. Levinson. Susan. Stossel. Thomas. DiNubile. Mark. Kobzik. Lester. Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia. Open Forum Infectious Diseases. 2017-10-04. 5630930.
  72. 0021-2938. 52. 1. 9–16. Vartanian. Amalia A. Gelsolin and plasminogen activator inhibitor-1 are Ap3A-binding proteins. The Italian Journal of Biochemistry. March 2003. 12833632.
  73. 10.1016/j.jmb.2006.01.027. 0022-2836. 357. 3. 765–772. Urosev. Dunja. Ma. Qing. Tan. Agnes L.C.. Robinson. Robert C.. Burtnick. Leslie D.. The Structure of Gelsolin Bound to ATP. Journal of Molecular Biology. 2006-03-31. 16469333.
  74. 10.1111/j.1432-1033.1995.001_c.x. 0014-2956. 234. 1. 1–7. Laham. Lorraine E.. Way. Michael. Yin. Helen L.. Janmey. Paul A.. Identification of Two Sites in Gelsolin with Different Sensitivities to Adenine Nucleotides. European Journal of Biochemistry. 1995-11-15. 8529627. free.
  75. 10.1093/oxfordjournals.jbchem.a123229. 0021-924X. 108. 4. 505–506. Yamamoto. Hideo. Ito. Hiroaki. Nakamura. Hideji. Hayashi. Eijiro. Kishimoto. Susumu. Hashimoto. Tadao. Tagawa. Kunio. Human Plasma Gelsolin Binds Adenosine Triphosphate. The Journal of Biochemistry. 2020-02-28. 1990-10-01. 1963427.
  76. 10.3233/JAD-141548. 1875-8908. 44. 1. 13–25. Ji. Lina. Zhao. Xi. Hua. Zichun. Potential Therapeutic Implications of Gelsolin in Alzheimer's Disease. Journal of Alzheimer's Disease. 2015-01-06. 25208622.
  77. 10.1093/emboj/17.20.5923. 1460-2075. 17. 20. 5923–5932. Meerschaert. K.. Gelsolin and functionally similar actin-binding proteins are regulated by lysophosphatidic acid. The EMBO Journal. 1998-10-15. 9774337. 1170920.
  78. 10.1074/jbc.275.19.14573. 0021-9258. 275. 19. 14573–14578. Goetzl. Edward J.. Lee. Hsinyu. Azuma. Toshifumi. Stossel. Thomas P.. Turck. Christoph W.. Karliner. Joel S.. Gelsolin Binding and Cellular Presentation of Lysophosphatidic Acid. Journal of Biological Chemistry. 2000-05-12. 10799543. free.
  79. 10.1021/bi0503504. 0006-2960. 44. 28. 9590–9597. Bucki. Robert. Georges. Penelope C.. Espinassous. Quentin. Funaki. Makoto. Pastore. Jennifer J.. Chaby. Richard. Janmey. Paul A.. Inactivation of Endotoxin by Human Plasma Gelsolin †. Biochemistry. 2005-07-19. 16008344.
  80. 10.1152/ajpcell.00510.2006. 0363-6143. 292. 4. –1323–C1330. Osborn. Teresia M.. Dahlgren. Claes. Hartwig. John H.. Stossel. Thomas P.. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. American Journal of Physiology. Cell Physiology. 2007-04-01. 17135294.
  81. 10.1016/S0006-8993(99)02315-X. 0006-8993. 853. 2. 344–351. Ray. Indrani. Chauhan. Abha. Wegiel. Jerzy. Chauhan. Ved P.S.. Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Research. 2000-01-24. 10640633. 41363612.
  82. 258. 2. 241–6. Chauhan. Ved P S. Ray. Indrani. Chauhan. Abha. Wisniewski. Henryk M. Binding of Gelsolin, a Secretory Protein, to Amyloid β-Protein. Biochemical and Biophysical Research Communications. 1999. 10.1006/bbrc.1999.0623. 10329371.
  83. 10.1152/ajpcell.00051.2010. 0363-6143. 299. 6. –1516–C1523. Bucki. Robert. Kułakowska. Alina. Byfield. Fitzroy J.. Żendzian-Piotrowska. Małgorzata. Baranowski. Marcin. Marzec. Michał. Winer. Jessamine P.. Ciccarelli. Nicholas J.. Górski. Jan. Drozdowski. Wiesław. Bittman. Robert. Janmey. Paul A.. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate. American Journal of Physiology. Cell Physiology. 2010-12-01. 20810916. 3006327.
  84. Hoffman SJ, Outterson K, Røttingen JA, Cars O, Clift C, Rizvi Z, Rotberg F, Tomson G, Zorzet A . An international legal framework to address antimicrobial resistance . Bulletin of the World Health Organization . 93 . 2 . 66 . February 2015 . 25883395 . 4339972 . 10.2471/BLT.15.152710 .
  85. Web site: O'Neill . Jim . Tackling drug-resistant infections globally: final report and recommendations . amr-review.org . Review on Antimicrobial Resistance . 5 March 2020.
  86. Web site: FACT SHEET: Obama Administration Releases National Action Plan to Combat Antibiotic-Resistant Bacteria . obamawhitehouse.archives.gov . 27 March 2015 . 5 March 2020.
  87. 10.1093/infdis/jiz353. 0022-1899. 220. 9. 1498–1502. Yang. Zhiping. Bedugnis. Alice. Levinson. Susan. Dinubile. Mark. Stossel. Thomas. Lu. Quan. Kobzik. Lester. Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia. The Journal of Infectious Diseases. 2019-09-26. 31287867. 6761947.
  88. 10.1165/rcmb.2002-0191OC. 1044-1549. 28. 6. 738–745. Weiner. Daniel J.. Bucki. Robert. Janmey. Paul A.. The Antimicrobial Activity of the Cathelicidin LL37 Is Inhibited by F-actin Bundles and Restored by Gelsolin. American Journal of Respiratory Cell and Molecular Biology. June 2003. 12600826.
  89. 0021-9258. 263. 17. 8239–8243. Kwiatkowski. D. J.. Mehl. R.. Izumo. S.. Nadal-Ginard. B.. Yin. H. L.. Muscle is the major source of plasma gelsolin. The Journal of Biological Chemistry. 1988-06-15. 10.1016/S0021-9258(18)68469-8. 2836420. free.
  90. 10.2174/138920308786733912. 1389-2037. 9. 6. 541–551. Bucki. Robert. Levental. Ilya. Kulakowska. Alina. Janmey. Paul A.. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Current Protein & Peptide Science. 2008-12-01. 19075745.
  91. 10.1016/j.mehy.2011.10.024. 0306-9877. 78. 2. 203–210. Peddada. Nagesh. Sagar. Amin. Ashish. Garg. Renu. Plasma gelsolin: A general prognostic marker of health. Medical Hypotheses. February 2012. 22082609.
  92. Self. Wesley H. Wunderink. Richard G. DiNubile. Mark J. Stossel. Thomas P. Levinson. Susan L. Williams. Derek J. Anderson. Evan J. Bramley. Anna M. Jain. Seema. Edwards. Kathryn M. Grijalva. Carlos G. 2019-09-13. Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes. Clinical Infectious Diseases. 69. 7. 1218–1225. 10.1093/cid/ciy1049. 30561561. 6743831. 1058-4838.
  93. 10.1186/cc6988. 1364-8535. 12. 4. –106. Wang. HaiHong. Cheng. BaoLi. Chen. QiXing. Wu. ShuiJing. Lv. Chen. Xie. GuoHao. Jin. Yue. Fang. XiangMing. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Critical Care. 2008. 18706105. 2575595. free.
  94. 10.1016/j.clinbiochem.2016.10.018. 0009-9120. 50. 3. 127–133. Horváth-Szalai. Zoltán. Kustán. Péter. Mühl. Diána. Ludány. Andrea. Bugyi. Beáta. Kőszegi. Tamás. Antagonistic sepsis markers: Serum gelsolin and actin/gelsolin ratio. Clinical Biochemistry. February 2017. 27823961.
  95. 10.1016/j.jcrc.2012.01.002. 0883-9441. 27. 5. 527–1–527.e6. Jin. Yong. Li. Bo-You. Qiu. Ling-Li. Ling. Yuan-Ren. Bai. Zhi-Qiang. Decreased plasma gelsolin is associated with 1-year outcome in patients with traumatic brain injury. Journal of Critical Care. 2020-03-04. 2012-10-01. 22386223.
  96. 10.1177/0961203313507985. 1477-0962. 22. 14. 1455–1461. Hu. Yl. Li. H.. Li. W. H.. Meng. H. X.. Fan. Y. Z.. Li. W. J.. Ji. Y. T.. Zhao. H.. Zhang. L.. Jin. X. M.. Zhang. F. M.. The value of decreased plasma gelsolin levels in patients with systemic lupus erythematosus and rheumatoid arthritis in diagnosis and disease activity evaluation. Lupus. December 2013. 24122723. 22637925.
  97. 10.1089/aid.2016.0154. 0889-2229. 33. 3. 254–260. Sinha. Kislay Kumar. Peddada. Nagesh. Jha. Pravin Kumar. Mishra. Anshul. Pandey. Krishna. Das. Vidya Nand Ravi. Ashish. Das. Pradeep. Plasma Gelsolin Level in HIV-1-Infected Patients: An Indicator of Disease Severity. AIDS Research and Human Retroviruses. March 2017. 27700141.
  98. 10.1159/000324373. 1660-2862. 8. 5. 375–380. Kułakowska. Alina. Zajkowska. Joanna M.. Ciccarelli. Nicholas J.. Mroczko. Barbara. Drozdowski. Wiesław. Bucki. Robert. Depletion of Plasma Gelsolin in Patients with Tick-Borne Encephalitis and Lyme Neuroborreliosis. Neurodegenerative Diseases. 2011. 21389683. 3121545.
  99. 10.1093/clinids/24.5.951. 1058-4838. 24. 5. 951–954. Huang. S.. Rhoads. S. L.. DiNubile. M. J.. Temporal association between serum gelsolin levels and clinical events in a patient with severe falciparum malaria. Clinical Infectious Diseases. May 1997. 9142799.
  100. 10.1371/journal.pone.0026495. 1932-6203. 6. 10. Kassa. Fikregabrail Aberra. Shio. Marina Tiemi. Bellemare. Marie-Josée. Faye. Babacar. Ndao. Momar. Olivier. Martin. New Inflammation-Related Biomarkers during Malaria Infection. PLOS ONE. 2011-10-20. e26495. 22028888. 3197653. 2011PLoSO...626495K. free.
  101. 10.1016/0016-5085(92)91731-i. 0016-5085. 102. 5. 1686–1692. Ito. H.. Kambe. H.. Kimura. Y.. Nakamura. H.. Hayashi. E.. Kishimoto. T.. Kishimoto. S.. Yamamoto. H.. Depression of plasma gelsolin level during acute liver injury. Gastroenterology. May 1992. 1314752. free.
  102. 10.1371/journal.pone.0025748. 1932-6203. 6. 11. –25748. Huang. Li-feng. Yao. Yong-ming. Li. Jin-feng. Dong. Ning. Liu. Chen. Yu. Yan. He. Li-xin. Sheng. Zhi-yong. Reduction of Plasma Gelsolin Levels Correlates with Development of Multiple Organ Dysfunction Syndrome and Fatal Outcome in Burn Patients. PLOS ONE. 2011-11-01. 22069445. 3206022. 2011PLoSO...625748H. free.
  103. 10.1016/j.burns.2014.02.020. 1879-1409. 40. 8. 1552–1555. Xianhui. Li. Pinglian. Li. Xiaojuan. Wang. Wei. Chen. Yong. Yang. Feng. Ran. Peng. Sun. Gang. Xue. The association between plasma gelsolin level and prognosis of burn patients. Burns: Journal of the International Society for Burn Injuries. December 2014. 24690274.
  104. 10.1164/ajrccm.160.5.9807137. 1535-4970. 160. 5. 1673–1681. Mounzer. Karam C.. Moncure. Michael. Smith. Yolanda R.. DiNUBILE. Mark J.. Relationship of Admission Plasma Gelsolin Levels to Clinical Outcomes in Patients after Major Trauma. American Journal of Respiratory and Critical Care Medicine. November 1999. 10556139.
  105. 10.1097/01.sla.0000201798.77133.55. 0003-4932. 243. 3. 399–403. Lee. Po-Shun. Drager. Leslie R.. Stossel. Thomas P.. Moore. Francis D.. Rogers. Selwyn O.. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Annals of Surgery. March 2006. 16495706. 1448930.
  106. 10.1182/blood-2002-06-1672. 1528-0020. 100. 13. 4367–4371. DiNubile. Mark J.. Stossel. Thomas P.. Ljunghusen. Olof C.. Ferrara. James L. M.. Antin. Joseph H.. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2020-02-12. 2002-12-15. 12393536. free.
  107. 10.1186/1471-2377-10-107. 1471-2377. 10. 1. 107. Kułakowska. Alina. Ciccarelli. Nicholas J. Wen. Qi. Mroczko. Barbara. Drozdowski. Wiesław. Szmitkowski. Maciej. Janmey. Paul A. Bucki. Robert. Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis. BMC Neurology. December 2010. 21040581. 2989318. free.
  108. 10.1371/journal.pone.0003712. 1932-6203. 3. 11. –3712. Lee. Po-Shun. Patel. Sanjay R.. Christiani. David C.. Bajwa. Ednan. Stossel. Thomas P.. Waxman. Aaron B.. Plasma Gelsolin Depletion and Circulating Actin in Sepsis—A Pilot Study. PLOS ONE. 2008-11-12. 19002257. 2577888. 2008PLoSO...3.3712L. free.
  109. 10.1016/j.bbalip.2012.06.014. 0006-3002. 1831. 1. 86–92. Zhao. Yutong. Natarajan. Viswanathan. Lysophosphatidic acid (LPA) and its Receptors: Role in Airway Inflammation and Remodeling. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. January 2013. 22809994. 3491109.
  110. 1550-6606. 127. 3. 1250–1255. Shaw. J. O.. Pinckard. R. N.. Ferrigni. K. S.. McManus. L. M.. Hanahan. D. J.. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor).. The Journal of Immunology. 2020-03-05. 1981-09-01. 10.4049/jimmunol.127.3.1250. 6267133. 23647018.
  111. 10.1007/s00281-011-0287-3. 1863-2300. 34. 1. 73–91. Obinata. Hideru. Hla. Timothy. Sphingosine 1-phosphate in coagulation and inflammation. Seminars in Immunopathology. 2012-01-01. 21805322. 3237867.
  112. 10.3390/ijms19092516. 1422-0067. 19. 9. Piktel. Ewelina. Levental. Ilya. Durnaś. Bonita. Janmey. Paul A.. Bucki. Robert. Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target. International Journal of Molecular Sciences. 2018-08-25. 2516. 30149613. 6164782. free.
  113. 0022-2143. 110. 2. 189–195. Smith. D. B.. Janmey. P. A.. Herbert. T. J.. Lind. S. E.. Quantitative measurement of plasma gelsolin and its incorporation into fibrin clots. The Journal of Laboratory and Clinical Medicine. August 1987. 3036979.
  114. 10.12688/f1000research.21082.2. 2046-1402. 8. 1860. Yang. Zhiping. Bedugnis. Alice. Levinson. Susan. DiNubile. Mark. Stossel. Thomas. Lu. Quan. Kobzik. Lester. Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza. F1000Research. 2020-02-21. 31824672. 6894358. free.
  115. 10.1152/japplphysiol.01074.2002. 8750-7587. 96. 1. 25–31. Rothenbach. Patricia A.. Dahl. Benny. Schwartz. Jason J.. O'Keefe. Grant E.. Yamamoto. Masaya. Lee. William M.. Horton. Jureta W.. Yin. Helen L.. Turnage. Richard H.. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. Journal of Applied Physiology. January 2004. 12730154.
  116. 10.1186/1742-2094-8-118. 1742-2094. 8. 1. 118. Zhang. Qing-Hong. Chen. Qi. Kang. Jia-Rui. Liu. Chen. Dong. Ning. Zhu. Xiao-Mei. Sheng. Zhi-Yong. Yao. Yong-Ming. Treatment with gelsolin reduces brain inflammation and apoptotic signaling in mice following thermal injury. Journal of Neuroinflammation. 2011-09-21. 21936896. 3191361. free.
  117. 10.1097/01.CCM.0000253815.26311.24. 0090-3493. 35. 3. 849–855. Lee. Po-Shun. Waxman. Aaron B.. Cotich. Kara L.. Chung. Su Wol. Perrella. Mark A.. Stossel. Thomas P.. Plasma gelsolin is a marker and therapeutic agent in animal sepsis*. Critical Care Medicine. 2020-02-12. March 2007. 17205019. 21641666.
  118. 10.1016/j.cyto.2011.02.006. 1043-4666. 54. 3. 235–238. Cohen. Taylor S.. Bucki. Robert. Byfield. Fitzroy J.. Ciccarelli. Nicholas J.. Rosenberg. Brenna. DiNubile. Mark J.. Janmey. Paul A.. Margulies. Susan S.. Therapeutic potential of plasma gelsolin administration in a rat model of sepsis. Cytokine. June 2011. 21420877. 3083472.
  119. 10.2310/6650.2002.33518. 1081-5589. 50. 1. 54–60. Christofidou-Solomidou. Melpo. Scherpereel. Arnaud. Solomides. Charalambos C.. Christie. Jason D.. Stossel. Thomas P.. Goelz. Susan. DiNubile. Mark J.. Recombinant Plasma Gelsolin Diminishes the Acute Inflammatory Response to Hyperoxia in Mice. Journal of Investigative Medicine. 2020-02-24. 2002-01-01. 11813829. 1981768.
  120. 10.1186/2040-7378-3-13. 2040-7378. 3. 1. 13. Le. Huong T. Hirko. Aaron C. Thinschmidt. Jeffrey S. Grant. Maria. Li. Zhimin. Peris. Joanna. King. Michael A. Hughes. Jeffrey A. Song. Sihong. The protective effects of plasma gelsolin on stroke outcome in rats. Experimental & Translational Stroke Medicine. 2011. 22047744. 3224589. free.
  121. 10.1016/j.jneuroim.2015.08.006. 0165-5728. 287. 36–42. Kevin Li-Chun. Hsieh. Schob. Stefan. Zeller. Matthias W.G.. Pulli. Benjamin. Ali. Muhammad. Wang. Cuihua. Chiou. Terry Ting-Yu. Tsang. Yuk-Ming. Lee. Po-Shun. Stossel. Thomas P.. Chen. John W.. Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis. Journal of Neuroimmunology. October 2015. 26439960. 4595933.
  122. 10.1038/sj.mt.6300253. 1525-0016. 15. 9. 1623–1629. Hirko. Aaron C. Meyer. Edwin M. King. Michael A. Hughes. Jeffery A. Peripheral Transgene Expression of Plasma Gelsolin Reduces Amyloid in Transgenic Mouse Models of Alzheimer's Disease. Molecular Therapy. September 2007. 17609655. free.
  123. 1529-2401. 23. 1. 29–33. Matsuoka. Yasuji. Saito. Mitsuo. LaFrancois. John. Saito. Mariko. Gaynor. Kate. Olm. Vicki. Wang. Lili. Casey. Evelyn. Lu. Yifan. Shiratori. Chiharu. Lemere. Cynthia. Duff. Karen. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. The Journal of Neuroscience. 2003-01-01. 10.1523/JNEUROSCI.23-01-00029.2003. 12514198. 6742136.
  124. 10.1007/s12013-014-0210-3. 1559-0283. 71. 1. 389–396. Li. Mingjuan. Cui. Fengmei. Cheng. Ying. Han. Ling. Wang. Jia. Sun. Ding. Liu. Yu-long. Zhou. Ping-kun. Min. Rui. Gelsolin: role of a functional protein in mitigating radiation injury. Cell Biochemistry and Biophysics. 2014-08-28. 25164111. 942471. 2020-02-25.
  125. 10.4103/0976-500X.103699. 0976-500X. 3. 4. 348. Gawade. Shivaji P.. Acetic acid induced painful endogenous infliction in writhing test on mice. Journal of Pharmacology & Pharmacotherapeutics. 2012. 2024-04-27. 23326113. 3543562. free.
  126. 10.1371/journal.pone.0135558. 1932-6203. 10. 8. –0135558. Gupta. Ashok Kumar. Parasar. Devraj. Sagar. Amin. Choudhary. Vikas. Chopra. Bhupinder Singh. Garg. Renu. Ashish. Khatri. Neeraj. Prasun K Datta (ed.). Analgesic and Anti-Inflammatory Properties of Gelsolin in Acetic Acid Induced Writhing, Tail Immersion and Carrageenan Induced Paw Edema in Mice. PLOS ONE. 2015-08-14. 26426535. 4537109. 2015PLoSO..1035558G. free.
  127. 10.1155/2014/152075. 2314-6745. 2014. 152075. Khatri. Neeraj. Sagar. Amin. Peddada. Nagesh. Choudhary. Vikas. Chopra. Bhupinder Singh. Garg. Veena. Garg. Renu. Ashish. Plasma Gelsolin Levels Decrease in Diabetic State and Increase upon Treatment with F-Actin Depolymerizing Versions of Gelsolin. Journal of Diabetes Research. 2014. 25478578. 4247973. free.
  128. BioAegis Therapeutics . A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP . ClinicalTrials.gov . 14 January 2020 . U.S. National Library of Medicine . 24 February 2020.
  129. Web site: BioAegis Therapeutics . Rhu-pGSN for Severe Covid-19 Pneumonia . ClinicalTrials.gov . U.S. National Library of Medicine . 16 July 2020.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Plasma gelsolin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.